This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.
Study Type
EXPANDED_ACCESS
Orca-T that does not meet commercial release specifications
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California, United States
AVAILABLEStanford Cancer Institute
Palo Alto, California, United States
AVAILABLEMoffitt Cancer Center
Tampa, Florida, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The University of Kansas Hospital
Kansas City, Kansas, United States
AVAILABLEMassachusetts General Hospital
Boston, Massachusetts, United States
AVAILABLEMemorial Sloan Kettering Cancer Center
New York, New York, United States
AVAILABLEThe Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio, United States
AVAILABLEBaylor University Medical Center
Dallas, Texas, United States
AVAILABLE